Inovio Pharmaceuticals, Inc. — FY2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017; filed March 14, 2018. The company is a clinical-stage biotechnology company developing DNA immunotherapies and vaccines using its SynCon and CELLECTRA platforms. It had no approved products or product sales; revenue came from collaborations, grants, and government contracts.
Financial performance and position
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $42.2 million | $35.4 million |
| Research and development expense | $98.6 million | $88.7 million |
| General and administrative expense | $28.3 million | $23.9 million |
| Operating loss | $83.6 million | $76.2 million |
| Net loss | $88.2 million | $73.7 million |
| Net loss per share, diluted | $1.09 | $1.01 |
| Net cash used in operating activities | $63.2 million | $62.6 million |
- Revenue rose 19%; collaboration revenue increased $21.3 million, mainly from MedImmune, while grants and miscellaneous revenue fell $14.4 million, largely as DARPA Ebola work neared completion. MedImmune, DARPA, and Roche accounted for 53%, 24%, and 14% of revenue, respectively.
- Net loss widened 20%, reflecting higher R&D and general and administrative spending and a $7.0 million loss on the fair value of the GeneOne investment. Operating expenses were substantially above revenue; the company remained loss-making and reported no meaningful commercial product margins.
- At year-end, cash and cash equivalents were $23.8 million and short-term investments were $103.6 million, totaling $127.4 million. Working capital was $103.0 million; current liabilities were $35.4 million. The filing reports no material long-term debt. Total liabilities were $44.8 million, including deferred rent and revenue.
- Management said existing cash and short-term investments were sufficient for planned working-capital needs for at least the next 12 months, while warning that continued development would require additional financing. FY2017 financing included $70.1 million net proceeds from a public offering and $24.2 million net proceeds from ATM share sales, with further ATM capacity of $18.9 million at year-end.
- Q4 2017 revenue was $8.8 million and net loss was $21.5 million, compared with $8.5 million revenue and $26.2 million net loss in Q4 2016.
Material developments, outlook, and risks
- VGX-3100 entered Phase 3 development for cervical dysplasia in June 2017. The parallel REVEAL studies were planned to enroll 198 patients each. A Phase 2 trial for vulvar lesions also began in 2017; the company planned a Phase 2 anal-lesion study in 2018.
- Other programs included clinical-stage candidates for HPV-related cancers, prostate cancer, HBV, HIV, Zika, Ebola, and MERS, as well as early-stage oncology combinations. These programs remained investigational; trial progress and early immune-response findings do not establish efficacy or approval.
- In December 2017, Inovio agreed to license VGX-3100 in Greater China to ApolloBio for a stated $23 million upfront payment, up to $20 million in regulatory milestones, and tiered royalties. The upfront payment depended on shareholder and regulatory approvals and was not yet received at year-end; the agreement could be terminated if payment was not made by April 7, 2018.
- MedImmune paid a $7 million milestone in December 2017 after initiation of the Phase 2 portion of a combination trial; MedImmune funds development of MEDI0457. Inovio also recognized $12.5 million of previously deferred collaboration revenue in 2017 after MedImmune selected a research-collaboration candidate.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, ongoing losses and financing needs, dilution from equity issuance, dependence on a small number of funders and collaborators, competition, manufacturing and supply constraints, and intellectual-property challenges. The company also depends on contract manufacturer VGXI, a GeneOne subsidiary, for plasmids.
- Operating lease commitments totaled $38.9 million, with facility leases extending as far as 2029. The company reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
- Management expects substantial operating losses for at least the next several years and does not expect product revenue for several years. No specific revenue, earnings, or clinical-success guidance was provided.
Important facts for investors to verify
- Whether ApolloBio’s approvals and $23 million upfront payment were completed by the stated deadline, and whether any territory or payment terms changed.
- VGX-3100 Phase 3 enrollment, timing, endpoint results, safety, and any regulatory feedback; also the status of the vulvar and planned anal programs.
- Cash burn, cash and investment balances, financing needs, and the effect of further share issuance on dilution.
- Future collaboration and grant funding, particularly the concentration of revenue in MedImmune, DARPA, and Roche and the transition of grant funding to contra-expense accounting in 2018.
- Clinical outcomes and safety data across the pipeline, and whether early immune-response findings translate into meaningful patient benefit.